Broad evidence since the 1970s has demonstrated that PRL can stimulate cells of both innate and adaptive immune systems [19] and therefore PRL has long been considered a potentially detrimental agent in MS and experimental autoimmune encephalomyelitis (EAE), the animal model for this disease. This evidence concerns the gene PRL and myeloid sarcoma.